BusinessAchillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCVBy Nasdaq OMXSep 9, 2016, 10:15 AM UTC
BusinessAchillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement WorkshopBy Nasdaq OMXSep 6, 2016, 10:05 AM UTC
BusinessOncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic CancerBy Nasdaq OMXSep 1, 2016, 12:01 PM UTC
BusinessAchillion to Present at Two Upcoming Investor ConferencesBy Nasdaq OMXSep 1, 2016, 10:05 AM UTC
BusinessSummit Reports Positive Phase 1 New Formulation Data and Outlines Route to Market Strategy for DMD Candidate EzutromidBy Nasdaq OMXAug 9, 2016, 11:00 AM UTC
BusinessOcera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of HepatologyBy Nasdaq OMXApr 11, 2016, 1:05 PM UTC
BusinessPositive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile InfectionBy Nasdaq OMXApr 11, 2016, 11:00 AM UTC
